CAVBP/DEP alternating chemotherapy for the treatment of intermediate and high grade non Hodgkin's lymphoma: final results of a pilot study

G. Palmieri, F. Caponigro, R. V. Iaffaioli, A. Contegiacomo, V. Montesarchio, R. Lauria, R. Calderopoli, C. Pagliarulo, C. Gridelli, A. R. Bianco

Research output: Contribution to journalArticle

Abstract

Between May 1984 and September 1986, 40 patients with intermediate or high grade non Hodgkin's lymphoma were treated with a novel protocol, which alternated a conventional regimen consisting of cyclophosphamide, doxorubicin, vincristine, bleomycin, and prednisone (CAVBP) with a second chemotherapy regimen, including two drugs with newly discovered activity against lymphomas, such as cis-platin, etoposide, and prednisone (DEO). Twenty-one patients (52.5 per cent) achieved a complete response, 11 patients (27.5 per cent) had a partial response. Eight of the 21 complete responders (38 per cent) relapsed 5 to 24 months after completion of treatment. With a median follow-up of over 40 months, 22 patients are alive, six with disease and three in a second complete response after salvage chemotherapy. Factors negatively associated with response included 'B' symptoms, advanced stage of disease, bulky tumour, poor performance status, number of extranodal sites of disease. 'B' symptoms, bulky tumour, and poor performance status were also negatively associated with survival. Toxicity was modest, with no treatment-related deaths and only six cases of severe leukopenia. The results of this pilot study do not justify comparison of CAVBP/DEP with more efficacious regimens in prospective, randomized trials.

Original languageEnglish
Pages (from-to)313-322
Number of pages10
JournalHematological Oncology
Volume8
Issue number6
Publication statusPublished - 1990

Keywords

  • Chemotherapy
  • lymphoma
  • non Hodgkin's
  • response
  • survival

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'CAVBP/DEP alternating chemotherapy for the treatment of intermediate and high grade non Hodgkin's lymphoma: final results of a pilot study'. Together they form a unique fingerprint.

  • Cite this

    Palmieri, G., Caponigro, F., Iaffaioli, R. V., Contegiacomo, A., Montesarchio, V., Lauria, R., Calderopoli, R., Pagliarulo, C., Gridelli, C., & Bianco, A. R. (1990). CAVBP/DEP alternating chemotherapy for the treatment of intermediate and high grade non Hodgkin's lymphoma: final results of a pilot study. Hematological Oncology, 8(6), 313-322.